A previous study discovered that plasma fasting insulin and leptin levels decreased in the GLP-1 (rhGLP-1) Beinaglutide (BN) treated mice, suggesting that BN could reduce hyperinsulinemia and hyperleptinemia associated with obesity (29). The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.